Does response to antiviral therapy affect the clinical long-term outcome of hepatitis delta?

Background: Hepatitis delta is the most severe form of viral hepatitis. Pegylated interferon alpha (PEG-IFNa) is effective in only 25 – 30% of patients and associated with frequent side effects. The aim of this study was to analyze the outcome of hepatitis delta according to different management strategies (no treatment, nucleos(t)ide therapies, interferon-based therapies).